Do you believe that N-of-1 trials (a clinical trial in which a single patient is the entire trial), are appropriate to evaluate the effectiveness of genomic therapies for rare and/or common genetic disorders? Do gene-editing/targeting therapies have the potential to expedite the advancement of personalized medicine?

Saved in:
Bibliographic Details
Published in:Health Science Inquiry 2017-06, Vol.8 (1)
Main Author: Carter, Ronald F.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2562-7791
2562-7791
DOI:10.29173/hsi223